Toray, Japan Tobacco and Torii Launches Oral Anti-itch Drug Remitch
This article was originally published in PharmAsia News
Executive Summary
Japanese companies Toray, Japan Tobacco and Torii Pharmaceuticals March 24 launched oral anti-itch drug Remitch (nalfurafine) capsule in Japan. Originated by Toray, nalfurafine is a selective kappa-opioid receptor agonist and the first oral anti-itching treatment in Japan for hemodialysis patients resistant to existing treatments. The drug obtained approval Janu. 21 and is currently marketed by Torii. The Japan Society for Dialysis Therapy estimates there are more than 275,100 dialysis patients in Japan. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.